Drug Trial Radar · NCT04844866
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
Last checked: Nov 20, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
213
Planned (sponsor's estimate)
Start
Aug 18, 2021
Primary completion
Jan 15, 2025
Study completion Sep 30, 2031
Sponsor
- Lead sponsor
- Miltenyi Biomedicine GmbHIndustry
- Sponsor type
- Industry
- Collaborators
- ICON plc
- First posted
- Apr 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In the current protocol version, there are two parts. Part I is a pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell lymphoma, who are not eligible for high-dose chemotherapy and autologous stem cell transplantation. Part II is a Phase II single-arm, open-label, multi-centre study evaluating the efficacy and safety of MB-CART2019.1 in younger, fit participants with R-R DLBCL. Part II will start after completion of enrolment in Part I.
Conditions
- Diffuse Large B-cell Lymphoma
Interventions
MB-CART2019.1Genetic
MB-CART2019.1 is designed to effectively target malignant B cells in patients suffering from late stage haematological B-cell malignancies. MB-CART2019.1 consists of autologous cluster of differentiation CD20/CD19 chimeric antigen receptor (CAR) transduced CD4/CD8 enriched T cells, derived from a leukapheresis and processed by using the CliniMACS Prodigy® device.
Standard of CareDrug
Standard of Care
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part I: Event-free survivalTime frame: up to 30 weeks after randomisation
- Part II: Best objective response rateTime frame: up to 30 weeks after administration of MB-CART2019.1
Locations
51 sites in 14 countries. Site status is shown where the registry gives one.
LKH - Medizinische Universitaet Graz
Graz, Austria · Active not recruiting
Universitatsklinikum Innsbruck Universitatsklinik fur Innere Medizin V
Innsbruck, Austria · Recruiting
Ordensklinikum Linz GmbH Elisabethinen
Linz, Austria · Recruiting
Medizinische Universitaet Wien - Allgemeines Krankenhaus der Stadt Wien (AKH)
Vienna, Austria · Recruiting
Jules Bordet lnstitute
Anderlecht, Belgium · Recruiting
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
Leuven, Belgium · Recruiting
University Hospital Center Zagreb
Zagreb, Croatia · Recruiting
University Hospital Hradec Kralove
Hradec Králové, Czechia · Recruiting
FNsP Ostrava
Ostrava, Czechia · Recruiting
Helsinki University Comprehensive Cancer Center
Helsinki, Finland · Not yet recruiting
Oulu University Central Hospital
Oulu, Finland · Recruiting
Turku University Hospital
Turku, Finland · Recruiting
Centre Hospitalier Universitaire (CHU) - Hopital Henri Mondor
Créteil, France · Recruiting
CHRU de Lille - Hopital Claude Huriez
Lille, France · Active not recruiting
Centre Hospitalier Lyon Sud, Hospices Civils de Lyon Groupement Hospitalier Sud
Lyon, France · Active not recruiting
Centre Paoli Calmettes
Marseille, France · Active not recruiting
Centre Hospitalier Universitaire de Nantes (CHU de Nantes) - Hopital Hotel Dieu
Nantes, France · Active not recruiting
Centre Hospitalier Universitaire de Bordeaux - Hopital Haut-Leveque
Pessac, France · Recruiting
Centre Hospitalier Universitaire de Poitiers
Poitiers, France · Recruiting
Institut Universitaire du Cancer Service d´hématologie
Toulouse, France · Recruiting
CHU de Nancy Hopitaux de Brabois
Vandœuvre-lès-Nancy, France · Recruiting
Universitatsklinikum Augsburg
Augsburg, Germany · Recruiting
Universitaetsklinikum Knappschaftskrankenhaus Bochum der Ruhr-Universitat Bochum
Bochum, Germany · Recruiting
Universitaetsklinikum Koeln
Cologne, Germany · Recruiting
Klinikum Erlangen der Friedrich-Alexander-Universitaet Erlangen-Nuernberg
Erlangen, Germany · Recruiting
Universitaetsklinikum Essen
Essen, Germany · Recruiting
University Medical Center Hamburg-Eppendorf
Hamburg, Germany · Recruiting
Universitaetsklinikum Heidelberg
Heidelberg, Germany · Recruiting
Universitätsklinikum Leipzig
Leipzig, Germany · Recruiting
Klinikum der Universitat München, Studienzentrale fur Hematologie der Medizinischen Klinik II
München, Germany · Recruiting
University Hospital Regensburg
Regensburg, Germany · Recruiting
University Hospital of Tuebingen
Tübingen, Germany · Recruiting
Del-Pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet
Budapest, Hungary · Recruiting
Debreceni Egyetem - Orvos es Egeszsegtudomanyi Centrum (DEOEC) (University of Debrecen Medical and Health Science Center)
Debrecen, Hungary · Recruiting
Azienda Ospedaliera San Giovanni Battista Di Torino
Torino, Italy · Recruiting
Amsterdam Universitaire Medische Centra (UMC) - locatie Amsterdam Medisch Centrum (AMC)
Amsterdam, Netherlands · Recruiting
University Medical Center Groningen
Groningen, Netherlands · Recruiting
Leiden University Medical Center (LUMC)
Leiden, Netherlands · Recruiting
Erasmus University Medical Center
Rotterdam, Netherlands · Active not recruiting
Uniwersytecki Szpital Kliniczny - Klinika Hematologii, Terapii Komorkowych i Chorob Wewnetrznych
Wroclaw, Poland · Active not recruiting
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.